Xcell Therapeutics Inc. Logo

Xcell Therapeutics Inc.

Develops and produces serum-free, chemically defined media for cell culture.

373110 | KO

Overview

Corporate Details

ISIN(s):
KR7373110006
LEI:
Country:
South Korea
Address:
서울특별시 강남구 영동대로 333 동원빌딩 6층, 강남구

Description

Xcell Therapeutics Inc. is a company specializing in the research, development, and production of advanced cell culture media. Its primary product line, CellCor™, consists of serum-free, chemically defined media designed to provide an optimal environment for cell culture, particularly for mesenchymal stem cells (MSCs). The technology aims to enhance efficiency and yield for researchers and developers in the fields of cell therapy and regenerative medicine. By offering a serum-free alternative, the company provides a more consistent and defined solution compared to traditional media. Xcell Therapeutics is also expanding its services to become a Contract Development and Manufacturing Organization (CDMO) and is exploring applications for its media in the cultured meat sector.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-16 00:00
기업설명회(IR)개최
Korean 6.7 KB
2025-09-19 00:00
임원ㆍ주요주주특정증권등거래계획보고서
Korean 43.3 KB
2025-09-16 00:00
투자설명서
Korean 2.2 MB
2025-09-15 00:00
[기재정정]증권신고서(지분증권) (2025.11)
Korean 2.6 MB
2025-09-12 00:00
기업설명회(IR)개최
Korean 6.9 KB
2025-09-01 00:00
[기재정정]증권신고서(지분증권) (2025.11)
Korean 2.8 MB
2025-08-21 00:00
기업설명회(IR)개최
Korean 7.2 KB
2025-08-18 00:00
증권신고서(지분증권) (2025.11)
Korean 2.0 MB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.2 MB
2025-08-14 00:00
주요사항보고서(유상증자결정)
Korean 35.8 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 1.2 MB
2025-03-28 00:00
정기주주총회결과
Korean 19.2 KB
2025-03-28 00:00
주식매수선택권부여에관한신고
Korean 14.7 KB
2025-03-20 00:00
감사보고서제출
Korean 26.5 KB
2025-03-20 00:00
사업보고서 (2024.12)
Korean 431.9 KB

Automate Your Workflow. Get a real-time feed of all Xcell Therapeutics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Xcell Therapeutics Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Xcell Therapeutics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Biopharmaceutical firm developing cannabinoid-based medicines for inflammatory conditions.
United Kingdom
ANAN
Designs, develops, and manufactures molecular diagnostic solutions and instruments.
Türkiye
ANGEN
ANAVEX LIFE SCIENCES CORP. Logo
Clinical-stage biopharmaceutical company developing therapeutics for CNS disorders.
United States of America
AVXL
Anbio Biotechnology Logo
Develops and provides in-vitro diagnostic (IVD) solutions and instruments.
United States of America
NNNN
Anebulo Pharmaceuticals, Inc. Logo
Clinical-stage biotech developing therapies for acute cannabinoid intoxication.
United States of America
ANEB
AnGes, Inc. Logo
Biopharmaceutical firm developing gene-based and nucleotide-based medicines.
Japan
4563
Anika Therapeutics, Inc. Logo
A global joint preservation company developing solutions for orthopedic care.
United States of America
ANIK
ANIMALCARE GROUP PLC Logo
Develops and commercializes veterinary pharmaceutical products and services globally.
United Kingdom
ANCR
ANI PHARMACEUTICALS INC Logo
Develops, manufactures, and markets branded, generic, and OTC pharmaceutical products.
United States of America
ANIP
Annexin Pharmaceuticals AB Logo
Clinical-stage biotech developing a cell-protecting biologic for RVO and oncology.
Sweden
ANNX

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.